© BusinessWire
16.01.2026
VTGN
LISTED
NASDAQ
Rosen Law Firm Urges Vistagen Therapeutics, Inc. (NASDAQ: VTGN) Stockholders with Large Losses to Contact the Firm for Information About Their Rights
News Preview
Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of Vistagen Therapeutics, Inc. (NASDAQ: VTGN) common stock between April 1, 2024 and December 16, 2025, both dates inclusive (the “Class Period”). Vistagen is a clinical-stage biopharmaceutical company.
For more information, submit a form,...
Themefolio
Profiler
Peergroup
© Globe Newswire
16.01.2026
DBV
LISTED
EURONEXT
DBV Technologies Announces €166.7 Million in Gross Proceeds Following the Full Exercise of the ABSA Warrants and BS Warrants Issued on its March 2025 Financing
News Preview
Châtillon, France, January 16, 2026...
Themefolio
Profiler
Peergroup
© BusinessWire
16.01.2026
DMAC
LISTED
NASDAQ
DiaMedica Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction and acute ischemic stroke, today announced that on January 15, 2026, it granted options to purchase an aggregate of 50,000 shares of DiaMedica’s common stock to a newly hired non-e...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Leerverkaufsstatistiken, Hedge-Fund Aktivitäten und viele weitere nutzerwertige Informationen benutzerfreundlich aufbereitet
© BusinessWire
16.01.2026
RPTX
LISTED
NASDAQ
Repare Shareholders Approve Acquisition by XenoTherapeutics, Inc.
News Preview
Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a clinical-stage precision oncology company, today announced that its Shareholders (as defined below) have approved the acquisition of all of the issued and outstanding common shares of the Company (the “Common Shares” and the holders of the Common Shares, the “Shareholders”) by...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© PR Newswire
16.01.2026
ATOS
LISTED
NASDAQ
Atossa Therapeutics Receives FDA Orphan Drug Designation for (Z)-Endoxifen for the Treatment of Duchenne Muscular Dystrophy
News Preview
Designation further supports (Z)-Endoxifen program into rare pediatric neuromuscular disease along with previously received Rare Pediatric Disease DesignationSEATTLE, Jan. 16, 2026 /PRNewswire/ -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapies in oncology...
Themefolio
Profiler
Peergroup
© Globe Newswire
16.01.2026
CLC
LISTED
CSE
Christina Lake Cannabis Announces Sale of Bare Land
News Preview
Christina Lake Cannabis Corp. (CSE: CLC) sold 99 acres of non-core land in Christina Lake, BC for $551,000; proceeds support working capital....
Themefolio
Profiler
Peergroup
© BusinessWire
16.01.2026
SRRK
LISTED
NASDAQ
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
Scholar Rock (NASDAQ: SRRK; the “Company”) today announced that the company granted inducement equity awards covering an aggregate of 35,200 shares of its common stock to two newly hired employees, consisting of inducement stock options to purchase an aggregate of 20,400 shares of common stock and inducement restricted stock units, covering an agg...
Themefolio
Profiler
Peergroup
© Globe Newswire
16.01.2026
ANNX
LISTED
NASDAQ
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
News Preview
BRISBANE, Calif., Jan. 16, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that impact nearly 10 million people worldwide, today announced that it has granted inducement to two new non-executive employees under...
Themefolio
Profiler
Peergroup
© BusinessWire
16.01.2026
SVRA
LISTED
NASDAQ
Savara Announces New Employment Inducement Grant
News Preview
Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to two new employees.
On January 15, 2026, the Compensation Committee of Savara's Board of Directors granted the inducement awards to two new employees who recently joined the Company. The in...
Themefolio
Profiler
Peergroup
© PR Newswire
16.01.2026
MTVA
LISTED
NASDAQ
MetaVia Announces the Closing of $9.3 Million Underwritten Public Offering, Including Full Exercise of Allotment Option
News Preview
CAMBRIDGE, Mass., Jan. 16, 2026 /PRNewswire/ -- MetaVia Inc. (Nasdaq: MTVA) (MetaVia or the Company), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced the closing of its previously announced underwritten public offering of Class A Units and Class B Units for gross proceeds of approximately $9...
Themefolio
Profiler
Peergroup
© BusinessWire
16.01.2026
QTRX
LISTED
NASDAQ
Quanterix Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
Quanterix Corporation (“Quanterix” or the “Company”) (NASDAQ: QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced that on January 15, 2026, inducement grants (the “Inducement Grants”) were made to four employees in connection with the commencement of their employment. The...
Themefolio
Profiler
Peergroup
© BusinessWire
16.01.2026
STOK
LISTED
NASDAQ
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
News Preview
Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. The Company today announced that, effe...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© Globe Newswire
16.01.2026
LFCR
LISTED
NASDAQ
Lifecore Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
CHASKA, Minn., Jan. 16, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”) a fully integrated contract development and manufacturing organization (“CDMO”), today announced that on January 14, 2026, the Lifecore compensation committee approved grants under Lifecore’s Equity Inducement Plan, as amended (the “Inducement P...
Themefolio
Profiler
Peergroup
© BusinessWire
16.01.2026
VTGN
LISTED
NASDAQ
VTGN Investors Have Opportunity to Lead Vistagen Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
News Preview
The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Vistagen Therapeutics, Inc. (“Vistagen” or “the Company”) (NASDAQ: VTGN) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commiss...
Themefolio
Profiler
Peergroup
© Globe Newswire
16.01.2026
HKPD
LISTED
NASDAQ
Cellyan Biotechnology Co., Ltd Receives Nasdaq Notice of Bid Price Deficiency
News Preview
HONG KONG, Jan. 16, 2026 (GLOBE NEWSWIRE) -- Cellyan Biotechnology Co., Ltd (Nasdaq: HKPD) (the "Company"), a leading provider of over the counter (“OTC”) pharmaceutical cross-border e-commerce supply chain services in Hong Kong, today announced that it received a notification letter (the “Notification Letter”) dated January 12, 2026 from Nasdaq'...
Themefolio
Profiler
Peergroup
© BusinessWire
16.01.2026
BAYN
LISTED
XETR
Bayer welcomes the U.S. Supreme Court decision to review the Durnell case in the Roundup™ litigation
News Preview
The U.S. Supreme Court today announced that it will review the Durnell Roundup™ case. Monsanto petitioned the court to hear Durnell in April 2025 and address the split in authority among federal circuit courts on the application of federal preemption, a cross-cutting issue in the Roundup™ litigation. The company expects a decision on the merits du...
Themefolio
Profiler
Peergroup
© Globe Newswire
16.01.2026
ZBIO
LISTED
NASDAQ
Zenas BioPharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
News Preview
WALTHAM, Mass., Jan. 16, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of therapies for autoimmune diseases, today announced that on January 15, 2026 (the “Grant Date”), the Compensatio...
Themefolio
Profiler
Peergroup
© Globe Newswire
16.01.2026
XENE
LISTED
NASDAQ
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
VANCOUVER, British Columbia and BOSTON, Jan. 16, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need, today announced equity inducement grants to ten new non-o...
Themefolio
Profiler
Peergroup
© Globe Newswire
16.01.2026
CNTX
LISTED
NASDAQ
Context Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
PHILADELPHIA, Jan. 16, 2026 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging bispecific antibodies for solid tumors, today announced that Context has granted non-qualified stock option awards to purchase an aggregate of 120,000 shares of...
Themefolio
Profiler
Peergroup
© Globe Newswire
16.01.2026
CAMP
LISTED
NASDAQ
CAMP4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
News Preview
CAMBRIDGE, Mass., Jan. 16, 2026 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4” or “the Company”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels to treat a broad range of g...
Themefolio
Profiler
Peergroup
© Globe Newswire
16.01.2026
CRVS
LISTED
NASDAQ
Corvus Pharmaceuticals to Announce Results from Cohort 4 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis
News Preview
Company to host conference call and webcast on Tuesday, January 20, 2026 at 8:00 am ET / 5:00 am PT Company to host conference call and webcast on Tuesday, January 20, 2026 at 8:00 am ET / 5:00 am PT...
Themefolio
Profiler
Peergroup
© PR Newswire
16.01.2026
TLX
LISTED
ASX
First U.S. Patient Dosed in BiPASS: Phase 3 Prostate Cancer Diagnosis Study
News Preview
MELBOURNE, Australia and INDIANAPOLIS, Jan. 16, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces that the first patient in the United States (U.S.) has been dosed in BiPASS™ (Biopsy of the Prostate Avoidance Stratification Study), a Phase 3 trial to evaluate the use of Telix's commercial PSMA-PET...
Themefolio
Profiler
Peergroup
© PR Newswire
16.01.2026
ABBV
LISTED
EURONEXT
AbbVie Announces Topline Results for Epcoritamab (DuoBody® CD3xCD20) from Phase 3 EPCORE® DLBCL-1 Trial in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
News Preview
Based on the topline results from the EPCORE® DLBCL-1 trial, AbbVie along with partner Genmab will engage global regulatory authorities to discuss next stepsNORTH CHICAGO, Ill., Jan. 16, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced topline results from the Phase 3 EPCORE® DLBCL-1 trial evaluating epcoritamab, a T-cell engaging bispecif...
Themefolio
Profiler
Peergroup
© BusinessWire
16.01.2026
GMAB
LISTED
NASDAQ
Genmab Announces Topline Results for Epcoritamab (DuoBody® CD3xCD20) from Phase 3 EPCORE® DLBCL-1 Trial in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
News Preview
Genmab A/S (Nasdaq: GMAB) today announced topline results from the Phase 3 EPCORE DLBCL-1 trial evaluating epcoritamab, a T-cell engaging bispecific antibody administered subcutaneously, which demonstrated an improvement in progression-free survival (PFS) (HR: 0.74 [95% CI 0.60 to 0.92])* in patients treated with epcoritamab monotherapy. Additiona...
Themefolio
Profiler
Peergroup
© Newsfile
16.01.2026
FFNT
LISTED
CSE
CSE Bulletin: Delist - 4Front Ventures Corp. (FFNT)
News Preview
Toronto, Ontario--(Newsfile Corp. - Le 16 janvier/January 2026) - The subordinate voting shares of 4Front Ventures Corp. will be delisted from the CSE at market close today, January 16, 2026. 4Front Ventures Corp. is currently suspended. See Bulletin 2025-0510. _________________________________ Les actions &...
Themefolio
Profiler
Peergroup
© Globe Newswire
16.01.2026
TLX
LISTED
ASX
First U.S. Patient Dosed in BiPASS: Phase 3 Prostate Cancer Diagnosis Study
News Preview
MELBOURNE, Australia, Jan. 17, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces that the first patient in the United States (U.S.) has been dosed in BiPASS™ (Biopsy of the Prostate Avoidance Stratification Study), a Phase 3 trial to evaluate the use of Telix’s commercial PSMA-PET1 imaging age...
Themefolio
Profiler
Peergroup
© BusinessWire
16.01.2026
AGL
LISTED
NYSE
Deadline Alert: agilon health, inc. (AGL) Shareholders Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit
News Preview
Glancy Prongay & Murray LLP reminds investors of the upcoming March 2, 2026 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired agilon health, inc. (“agilon” or the “Company”) (NYSE: AGL) securities between February 26, 2025 and August 4, 2025, inclusive (the “Class Peri...
Themefolio
Profiler
Peergroup
© Globe Newswire
16.01.2026
GMAB
LISTED
CPH
Genmab Announces Topline Results for Epcoritamab (DuoBody® CD3xCD20) from Phase 3 EPCORE® DLBCL-1 Trial in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
News Preview
Company Announcement...
Themefolio
Profiler
Peergroup
© Newsfile
16.01.2026
HEM
LISTED
TSX
Hemostemix Receives FDA Support for Its Basket Protocol Approach
News Preview
Calgary, Alberta--(Newsfile Corp. - January 16, 2026) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0), the leading autologous stem cell company treating those who suffer in pain from peripheral arterial disease, chronic limb threatening ischemia, angina, ischemic cardiomyopathy, dilated cardiomyopathy, and vascular dementia, in Florida, Ca...
Themefolio
Profiler
Peergroup
© BusinessWire
16.01.2026
PRGO
LISTED
NYSE
PRGO Deadline: Rosen Law Firm Urges Perrigo Company plc (NYSE: PRGO) Investors to Contact the Firm for Information About Their Rights
News Preview
Rosen Law Firm, a global investor rights law firm, reminds investors that a class action lawsuit on behalf of purchasers of securities of Perrigo Company plc (NYSE: PRGO) between February 27, 2023 and November 4, 2025. Perrigo provides over-the-counter health and wellness solutions.
For more information, submit a form, email attorney Phillip Kim...
Themefolio
Profiler
Peergroup
© PR Newswire
16.01.2026
WWH
LISTED
LSE
Worldwide Healthcare Trust PLC - Transaction in Own Shares
News Preview
For immediate release
16 January 2026
WORLDWIDE HEALTHCARE TRUST PLC
(the "Company")
MARKET PURCHAS...
Themefolio
Profiler
Peergroup
© PR Newswire
16.01.2026
BRETEC
LISTED
HEL
CMS Transitional Pass-Through Payment (TPT) description for HCPCS code C1741 has been revised
News Preview
TAMPERE, Finland, Jan. 16, 2026 /PRNewswire/ -- Bioretec Ltd, a pioneer in absorbable orthopedic implants, was granted Transitional Pass-Through Payment (TPT) status by the U.S. Centers for Medicare & Medicaid Services (CMS) for its RemeOs™ Trauma Screw, effective October 1, 2025.
CMS subsequently released an update to the HCPCS Level II codes...
Themefolio
Profiler
Peergroup
© PR Newswire
16.01.2026
BRETEC
LISTED
HEL
CMS Transitional Pass-Through Payment (TPT) description for HCPCS code C1741 has been revised
News Preview
TAMPERE, Finland, Jan. 16, 2026 /PRNewswire/ -- Bioretec Ltd, a pioneer in absorbable orthopedic implants, was granted Transitional Pass-Through Payment (TPT) status by the U.S. Centers for Medicare & Medicaid Services (CMS) for its RemeOs™ Trauma Screw, effective October 1, 2025.
CMS subsequently released an update to the HCPCS Level II codes...
Themefolio
Profiler
Peergroup
© PR Newswire
16.01.2026
GEHC
LISTED
NASDAQ
Bedside Breakthrough: AI Brings MRI-Precision to Every Clinic
News Preview
ISSUED ON BEHALF OF VENTRIPOINT DIAGNOSTICS LTD.USANewsGroup.com News Commentary VANCOUVER, BC, Jan. 16, 2026 /PRNewswire/ -- The medical imaging world is hitting a massive reset button as AI-driven clinical intelligence transforms how we map the human heart. With the medical image management market projected to hit $9.06 billion by 2032[1], the e...
Themefolio
Profiler
Peergroup
© PR Newswire
16.01.2026
GEHC
LISTED
NASDAQ
Bedside Breakthrough: AI Brings MRI-Precision to Every Clinic
News Preview
ISSUED ON BEHALF OF VENTRIPOINT DIAGNOSTICS LTD.USANewsGroup.com News Commentary VANCOUVER, BC, Jan. 16, 2026 /CNW/ -- The medical imaging world is hitting a massive reset button as AI-driven clinical intelligence transforms how we map the human heart. With the medical image management market projected to hit $9.06 billion by 2032[1], the era of b...
Themefolio
Profiler
Peergroup
© Globe Newswire
16.01.2026
AGFB
LISTED
EURONEXT
Agfa receives final expert ruling on receivable related to sale of Offset Solutions division to Aurelius
News Preview
...
Themefolio
Profiler
Peergroup
© BusinessWire
16.01.2026
ERF
LISTED
EURONEXT
Eurofins Scientific: Director/PDMR Shareholding
News Preview
Eurofins Scientific SE (EUFI.PA) (Paris:ERF) has received various notifications of dealing from Persons Discharging Managerial Responsibilities (“PDMR”). The notification of Dealing Form for each PDMR can be found below.
This notification is made in accordance with the European Market Abuse Regulation.
NOTIFICATION AND PUBLIC DISCLOSURE OF T...
Themefolio
Profiler
Peergroup
© PR Newswire
16.01.2026
WWH
LISTED
LSE
Worldwide Healthcare Trust PLC - Net Asset Value(s)
News Preview
WORLDWIDE HEALTHCARE TRUST PLC
LEI: 5493003YBCY4W1IMJU04
NET ASSET VALUE
The estimated un-audited net asset val...
Themefolio
Profiler
Peergroup
© EQS Newswire
16.01.2026
SKNY
LISTED
CSE
Start der “In-vivo-Studie” markiert wichtigen Entwicklungsschritt der transdermalen Adipositas-Plattform
News Preview
EQS-Media / 16.01.2026 / 15:10 CET/CEST
LIR Life Sciences Corp. (ISIN: CA50206C1005 | WKN: A41QA9), LIR oder das Unternehmen, freut sich, den Start einer kontrollierten vergleichenden Tierstudie bekannt zu geben, die darauf abzielt, die nadelfreie transdermale Verabreichung von “GLP”/ “GIP”-basierten Adipositas-Therapien der zweiten Generation......
Themefolio
Profiler
Peergroup
© PR Newswire
16.01.2026
POM
LISTED
NASDAQ
POMDOCTOR LIMITED Drive Internet Hospital Growth Through Strengthened Strategic Partnerships With Pharmaceutical Companies
News Preview
GUANGZHOU, China, Jan. 16, 2026 /PRNewswire/ -- POMDOCTOR LIMITED ("Pomdoctor" or the "Company") (NASDAQ: POM), a leading online medical services platform for chronic diseases in China, today announced significant progress in its strategic collaboration with leading domestic pharmaceutical companies to accelerate the growth of its internet hospita...
Themefolio
Profiler
Peergroup
© PR Newswire
16.01.2026
CRDL
LISTED
TSX
Canadian Investment Regulatory Organization Trade Resumption - CRDL
News Preview
TORONTO, Jan. 16, 2026 /CNW/ - Trading resumes in:
Company: Cardiol Therapeutics Inc.TSX Symbol: CRDLAll Issues: YesResumption (ET): 9:00 AMCIRO can make a decision to impose a temporary suspension (halt) of trading in a security of a publicly-listed company. Trading halts are implemented to ensure a fair and orderly market. CIRO is the national s...
Themefolio
Profiler
Peergroup
© Newsfile
16.01.2026
CRDL
LISTED
TSX
Cardiol Therapeutics Announces Bought Deal Financing for Gross Proceeds of $13.5 Million
News Preview
Toronto, Ontario--(Newsfile Corp. - January 16, 2026) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease, today announced that it has entered into an agreement with a sole under...
Themefolio
Profiler
Peergroup
© PR Newswire
16.01.2026
VNRX
LISTED
XASE
Volition Sponsors Symposium at Veterinary Meeting and Expo
News Preview
HENDERSON, Nev., Jan. 16, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, announces the sponsorship of an industry symposium at the world's leading veterinary education conference, Veterinary Meeting and Expo ("VMX") in Orlando, Florida.
Dr. Sue Ettinger, DVM, DACVIM (Oncology) aka...
Themefolio
Profiler
Peergroup
© Newsfile
16.01.2026
CRDL
LISTED
TSX
Cardiol Therapeutics Inc. Announces Bought Deal Financing for Gross Proceeds of $13.5 Million
News Preview
Toronto, Ontario--(Newsfile Corp. - January 16, 2026) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease, today announced that it has entered into an agreement with Canaccord Ge...
Themefolio
Profiler
Peergroup
© PR Newswire
16.01.2026
CRDL
LISTED
TSX
Canadian Investment Regulatory Organization Trading Halt - CRDL
News Preview
TORONTO, Jan. 16, 2026 /CNW/ - The following issues have been halted by CIRO:
Company: Cardiol Therapeutics Inc.TSX Symbol: CRDL All Issues: YesReason: Pending News Halt Time (ET): 8:10 AMCIRO can make a decision to impose a temporary suspension (halt) of trading in a security of a publicly-listed company. Trading halts are implemented to ensure a...
Themefolio
Profiler
Peergroup
© PR Newswire
16.01.2026
CHRS
LISTED
NASDAQ
Functional Force: Precision Platforms Disrupt the 2026 Tumor Landscape
News Preview
Issued on behalf of GT Biopharma, Inc.VANCOUVER, BC, Jan. 16, 2026 /PRNewswire/ -- Equity Insider News Commentary – The precision medicine sector is undergoing a structural realignment toward platform-based biologics, as the market prepares to surge from $138 billion this year to over $537 billion by 2035[1]. This shift marks the end of "one-size-...
Themefolio
Profiler
Peergroup
© PR Newswire
16.01.2026
2696
LISTED
HKSE
Henlius Showcases "Globalisation 2.0" Strategy and Mid-to-Long-Term Innovation Blueprint at JPM 2026
News Preview
SAN FRANCISCO, Jan. 16, 2026 /PRNewswire/ -- The 44th J.P.Morgan Healthcare Conference (JPMHC) was successfully held in San Francisco, the United States, from January 12 to 15. As one of the most influential annual events in the global healthcare sector, JPM serves as a key platform for the capital markets and industry leaders to observe emerging...
Themefolio
Profiler
Peergroup
© PR Newswire
16.01.2026
CHRS
LISTED
NASDAQ
Functional Force: Precision Platforms Disrupt the 2026 Tumor Landscape
News Preview
Issued on behalf of GT Biopharma, Inc.VANCOUVER, BC, Jan. 16, 2026 /CNW/ -- Equity Insider News Commentary – The precision medicine sector is undergoing a structural realignment toward platform-based biologics, as the market prepares to surge from $138 billion this year to over $537 billion by 2035[1]. This shift marks the end of "one-size-fits-al...
Themefolio
Profiler
Peergroup
© PR Newswire
16.01.2026
2696
LISTED
HKSE
Henlius Showcases "Globalisation 2.0" Strategy and Mid-to-Long-Term Innovation Blueprint at JPM 2026
News Preview
SAN FRANCISCO, Jan. 16, 2026 /PRNewswire/ -- The 44th J.P.Morgan Healthcare Conference (JPMHC) was successfully held in San Francisco, the United States, from January 12 to 15. On January 15 (PST), Dr. Jason Zhu, Executive Director and Chief Executive Officer of Shanghai Henlius Biotech, Inc. (2696.HK), delivered a keynote presentation outlining H...
Themefolio
Profiler
Peergroup
© PR Newswire
16.01.2026
WWH
LISTED
LSE
Worldwide Healthcare Trust PLC - Monthly Fact Sheet as at 31 December 2025
News Preview
Worldwide Healthcare Trust PLC
(the "Company")
16 January 2026
LEI: 5493003YBCY4W1IMJU04
Monthly Fact Shee...
Themefolio
Profiler
Peergroup
© PR Newswire
16.01.2026
BKD
LISTED
NYSE
Brookdale Announces 2026 Investor Day and Webcast
News Preview
BRENTWOOD, Tenn., Jan. 16, 2026 /PRNewswire/ -- Brookdale Senior Living Inc. (NYSE: BKD) announced that it will host an Investor Day meeting in Nashville, TN on January 30, 2026. The event, which will also be webcast live, will commence at approximately 9:00 a.m. Central Time and will end at approximately 12:00 p.m. The meeting will feature presen...
Themefolio
Profiler
Peergroup
© Globe Newswire
16.01.2026
VVOS
LISTED
NASDAQ
Vivos Therapeutics Announces Exercise of Warrants for $4.64 Million Gross Proceeds
News Preview
Vivos Therapeutics Announces Exercise of Warrants for $4.64 Million Gross Proceeds...
Themefolio
Profiler
Peergroup
© Globe Newswire
16.01.2026
EXE
LISTED
TSX
Extendicare Announces Timing of 2025 Fourth Quarter Results and Conference Call
News Preview
MARKHAM, Ontario, Jan. 16, 2026 (GLOBE NEWSWIRE) -- Extendicare Inc. (“Extendicare” or the “Company”) (TSX: EXE) announced today that it plans to release its financial results for the fourth quarter of 2025 after market close on Thursday, February 26, 2026. A conference call hosted by Michael Guerriere, President and Chief Executive Officer and D...
Themefolio
Profiler
Peergroup
© Globe Newswire
16.01.2026
ELTX
LISTED
NASDAQ
Elicio Therapeutics Reports Inducement Grants
News Preview
BOSTON, Jan. 16, 2026 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio” or the “Company”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced that on January 15, 2026, Elicio granted an aggregate of 22,400 inducement stock options to two new employ...
Themefolio
Profiler
Peergroup
© Newsfile
16.01.2026
OPTI
LISTED
CSE
Optimi Health Announces Equity Incentive Grants and Corporate Update
News Preview
Vancouver, British Columbia--(Newsfile Corp. - January 16, 2026) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) ("Optimi" or the "Company"), a Canadian GMP-compliant manufacturer of MDMA and psilocybin, today announced a series of equity compensation and marketing initiatives designed to support its growth strategy and enhance market a...
Themefolio
Profiler
Peergroup
© BusinessWire
16.01.2026
IBRX
LISTED
NASDAQ
ImmunityBio Advances First-Line BCG Naive NMIBC Program with Enrollment Exceeding Expectations and Positive Interim Analysis for ANKTIVA® Plus BCG
News Preview
ImmunityBio, Inc. (NASDAQ: IBRX) today announced an update on the status of enrollment in its randomized registrational trial in BCG-naïve non-muscle-invasive bladder cancer (NMIBC), QUILT-2.005. Enrollment has exceeded internal expectations and is now over 85% complete, with full enrollment of the planned study population anticipated by Q2 2026....
Themefolio
Profiler
Peergroup
© BusinessWire
16.01.2026
IBRX
LISTED
NASDAQ
ImmunityBio Announces Durable Complete Response of 15 Months with a Chemotherapy-Free CD19 CAR-NK Cell Therapy in Waldenstrom Lymphoma
News Preview
ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced updated efficacy and safety results from the ongoing QUILT-106 clinical study (NCT06334991) evaluating an off-the-shelf allogeneic CD19 chimeric antigen receptor natural killer cell therapy (CAR-NK). This CD19 t-haNK (CAR-NK) is a targeted high-affinity nat...
Themefolio
Profiler
Peergroup
© PR Newswire
16.01.2026
SOBI
LISTED
STO
Sobi Receives European Commission Approval for Aspaveli® (pegcetacoplan) for the Treatment of C3G and Primary IC-MPGN
News Preview
Approximately 8,000 people in Europe are living with C3G or primary IC-MPGN Aspaveli (pegcetacoplan) is the first treatment of primary IC-MPGN and the first treatment for C3G and primary IC-MPGN for patients 12 years and olderSTOCKHOLM, Jan. 16, 2026 /PRNewswire/ -- Sobi® (STO: SOBI), today announced that the European Commission (EC) has approved...
Themefolio
Profiler
Peergroup
© Globe Newswire
16.01.2026
NRXP
LISTED
NASDAQ
NRx Pharmaceuticals (Nasdaq:NRXP) Announces 2025 Annual Meeting Date and Record Date
News Preview
WILMINGTON, Del., Jan. 16, 2026 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (Nasdaq:NRXP) (the “Company”), a clinical-stage biopharmaceutical company, today announced that it will hold its annual meeting of stockholders (the “2025 Annual Meeting”) on March 23, 2026 at 10:00 a.m. Eastern Time, in virtual-only format at https://www.cstproxy.com/n...
Themefolio
Profiler
Peergroup
© Globe Newswire
16.01.2026
EYPT
LISTED
NASDAQ
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
News Preview
WATERTOWN, Mass., Jan. 16, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious retinal diseases, today announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company’s...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
